China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...

(Oldenburg, IN) – Oldenburg Academy teacher Helen Yane has been awarded the Lilly Teacher Creativity Fellowship. According to the Lilly Endowment, this competitive program “enables educators to pursue ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

Eli Lilly spooked the market with warnings of a small revenue slowdown in Q4 2024. Lilly nevertheless delivered good news about its prospects for sales growth in 2025. The company also dropped a ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...